



Jim Joyce
CEO, Inventor

FORWARD-LOOKING STATEMENTS

The following presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Sigyn Therapeutics, Inc. ("Sigyn"). All statements in this presentation, other than statements of historical fact, are forward-looking statements within the meaning of federal securities laws. In some cases, you can identify forward-looking statements by terms such as "may," "will," "expect," "plan," "anticipate," "strategy," "designed," "intend," "believe," "estimate," "target," or "potential" and other similar expressions. Forward-looking statements involve risks, uncertainties and assumptions that may cause Sigyn's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation, including risks and uncertainties inherent in Sigyn's business and other risks described in Sigyn's filings with the Securities and Exchange Commission (SEC). Sigyn's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Sigyn's periodic reports filed with the SEC, which are available on the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Sigyn undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

A close-up, slightly blurred photograph of medical equipment. In the foreground, a clear plastic cylindrical filter is visible, with a blue plastic clamp at the top and a yellow plastic connector on the side. Red and white medical tubing are connected to the filter. The background is out of focus, showing more of the same equipment.

Addressing the #1 Cause of Global Deaths



Sigyn CardioDialysis™

A close-up, slightly blurred photograph of a medical device. It features a clear plastic cylindrical component with a blue plastic connector on top. Red and white medical tubing are connected to the device. The background is out of focus, showing more of the device and tubing.

A First-in-Industry Medical Device to Treat Cardiovascular Disease

About Cardiovascular Disease (CVD)

- Leading cause of death worldwide, responsible for ~1/3 of annual fatalities
- Primary clinical endpoint to evaluate CVD therapies is reduction of Major Adverse Cardiovascular Events (MACE)
- Market for MACE reduction therapies estimated at \$150-200 Billion


About CardioDialysis™

- Objective of CardioDialysis™ is to enhance and extend the lives of individuals with cardiovascular disease (CVD)
- Deployed on the dialysis machine infrastructure that currently extends the lives of individuals with end-stage renal disease (ESRD)
- Mechanism overcomes limitation of single-target CVD drugs
- Targets MACE reduction through the simultaneous clearance of inflammatory molecules and cholesterol-transporting lipoproteins

Notable Therapies to Reduce MACE

- **DRUGS** - Statins (Lipitor, Crestor, Zocor, etc.) that target LDL-C reduction are leading class of CVD drugs that reduce MACE by **25-35%**
- **MEDICAL DEVICES** - Lipoprotein Apheresis (LA) (Kaneka Liposorber, Fresenius DALI, MONET) that reduce LDL-C and Lp(a) from the bloodstream report **55-98% reductions in MACE**


Note: LA treatments are limited to specialized apheresis centers. As an example, Liposorber therapy is limited to fewer than 60 locations in the U.S.



Sigyn CardioDialysis™

An Emerging Strategy to Reduce MACE

- Targets both LDL-C and Lp(a) reduction (*proven to significantly reduce MACE*)
- Simultaneous reduction of inflammatory molecules that drive CVD progression
- Deployed on dialysis machines already located in 7,500+ U.S. Dialysis Clinics



Sigyn CardioDialysis™

An Emerging Strategy to Reduce MACE

- Highly Efficient – Processes the bloodstream ~15 times during a four-hour treatment
- Immense Capacity - Incorporates a formulation of adsorbent components with ~200,000 M² of surface area (50 acres) to remove CVD targets

An Opportunity to Transform the Dialysis Industry

- Extending the lives of end-stage renal disease (ESRD) patients has quantifiable value to the dialysis industry
- CardioDialysis™ establishes a pathway to treat CVD in the general population - the focal point of Lipoprotein Apheresis
- We envision today's kidney dialysis clinics as being *"Renal and CardioDialysis Treatment Centers"* in the future

CVD in End-Stage Renal Disease (ESRD) Dialysis Patients

- 550,000+ ESRD patients receive ~85 million dialysis treatments in the U.S. each year
- Annual mortality rate is ~20%
- Cardiovascular Disease (CVD) is the leading cause of ESRD patient deaths
- Endotoxemia, concurrent inflammation, and Lp(a) accumulation increases the incidence of MACE

Two Organizations Dominate The U.S. Dialysis Industry



38% Market Share



37% Market Share

The Value of Extending ESRD Patient Lives



**~\$1 billion of added revenue per Company
for each month of extended life**

The Value of Reducing ESRD Patient Hospitalizations



~\$250 million of recouped revenues per Company
for each week of reduced hospitalization

Sigyn CardioDialysis™ Clinical Plan

- Investigation Device Exemption (IDE) drafted for FDA submission
- Feasibility study protocol to enroll 12-15 ESRD subjects at three site locations
- Sigyn CardioDialysis™ to be administered in series with regular dialysis treatments
- Primary endpoint is safety / secondary endpoints – LDL-C & Lp(a) reduction / quantification of endotoxin and inflammatory cytokine levels
- Study completion sets stage for ESRD subject pivotal study and establishes a potential pathway to initiate cardiovascular disease studies in the general (non-ESRD) population

Analyst Question?

How would you value a cardiovascular disease (#1 cause of global deaths) therapy that reduced Major Adverse Cardiovascular Events (MACE) in the general population?



Sigyn CardioDialysis™

A close-up, slightly blurred photograph of a medical device. It features a clear plastic cylindrical component with a blue plastic connector on top. Red and white medical tubing are connected to the device. The background is out of focus, showing more of the device and tubing.

A First-in-Industry Medical Device to Treat Cardiovascular Disease

A close-up, slightly blurred photograph of medical equipment. In the foreground, a clear plastic tube with a yellow Luer-lock connector is visible. In the background, a red tube is connected to a blue Luer-lock connector on a clear plastic container. The overall scene suggests a medical or laboratory setting.

The #1 Cause of Global Deaths



Jim Joyce
CEO, Inventor